Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAFT: Oral FMT for Prevention of Recurrent C. difficile Infection
NCT03621657Phase 2Completed
- Sponsor
- University of Wisconsin–Madison
- Start
- Mar 2019
- Primary completion
- Feb 2020
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Fecal Microbiota Transplantation Capsule in Clostridioides difficile infection (CDI) (3 arms), sponsored by University of Wisconsin–Madison. Primary endpoint: Composition and Function of the Gut Microbiota at 60 days. Started Mar 2019; status: completed.
02
Drugs
Fecal Microbiota Transplantation Capsule
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT03621657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03621657.